ClinicalTrials.gg
Not yet recruitingNCT07946341Updated Nov 18, 2026

A Study in Healthy Participants With Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380

A Phase 1 interventional study of CS060380 and Placebo in MASH (Metabolic Dysfunction-Associated Steatohepatitis), sponsored by Cascade Pharmaceuticals, Inc. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Cascade Pharmaceuticals, Inc · Phase 1, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 212 studies in Fatty Liver with a site in United States — 42 open to participants now, 48 under way, 8 of them phase 3. Fatty Liver · United States.

Planned enrollment
97th of 163
30 · median 44
Started
2026
with 14 others
Phase 1
19 of 212
4 open now
Primary completion
2027-03
later than 14 of 47 live
Registered
212th of 212
by date

Among the 212 studies in Fatty Liver with a site in United States, this one is the 97th largest by planned enrollment of the 163 interventional ones that give a count, is one of 15 that started in 2026, is one of 19 in phase 1, reaches primary completion later than 14 of the 47 other live ones, and was the 212th registered.

Fatty Liver

664 studies on the registry are indexed under Fatty Liver; 186 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

42 of the 212 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 212 studies in Fatty Liver with a site in United States, or all of them as a file.
02

Study summary

A study in Healthy Participants with Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, PK and PD of CS060380 following oral multiple ascending dose administration in healthy participants with elevated LDL-C.

Approximately 30 participants (10 participants per cohort: n=8 participants will receive active CS060380 and n=2 participants will be administered placebo) will be enrolled sequentially in 3 ascending dose groups. The proposed dose levels will range from 1.0 mg to 4.0 mg.

The next higher dose cohort will be enrolled only after the prior dose cohort has been discharged from the CPC on Day 17 and the SRC has reviewed all available safety/tolerability, PK/PD, and thyroid function data.

03

Conditions studied

  • MASH (Metabolic Dysfunction-Associated Steatohepatitis)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant provided signed and dated .
  2. Male or female aged 18-65 years (inclusive).
  3. Fasting LDL-C >110 mg/dL (2.85 mmol/L) at screening.
  4. Female participants must meet one of the following:

    1. status confirmed by follicle-stimulating hormone (FSH) testing, or
    2. Surgically sterile (medically documented), or
    3. If with , the participant must agree to use at least one highly effective method in combination with an additional effective contraceptive method from study initiation until 3 months after the last dose, or
    4. Complete abstinence (if agreed by the participant).

    Male participants, even if surgically sterilized (e.g., vasectomy), must:

    1. Use effective barrier contraception and refrain from sperm donation throughout the study and for 3 months after the last dose, or
    2. Complete abstinence (if agreed upon by the participant). Refer to Section 9.4 for detailed contraceptive requirements.
  5. Normal renal function (estimated [eGFR] ≥ 80 mL/min/1.73 m², calculated using the CKD-EPI equation).
  6. Good general health, as judged by the Investigator based on: medical/surgical history, complete physical examination, vital signs, laboratory tests, and 12-lead results (all findings either normal or with no abnormalities).
  7. No significant medical history; assessed to be in good general health at screening, with evaluations completed ≤ 28 days before the first dose.
  8. Willingness and ability to: Understand and comply with study procedures/restrictions, complete the trial as planned and communicate effectively with the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with special dietary requirements unable to comply with standardized diets.
  2. Females who are pregnant or lactating, those with pregnancy plans within 3 months post-trial, or female participants with positive pregnancy tests during screening/baseline periods.
  3. Participants with febrile illness or active infection within 7 days prior to the first dose of the drug.
  4. Participants with positive urine drug screening results.
  5. Participants with a history of drug/substance abuse within 5 years prior to the trial or positive drug screening at Day -1.
  6. Participants receiving lipid-lowering therapy or with LDL-C > 190 mg/dL, or those with a history of coronary artery disease, cardiac arrhythmias, unexplained syncope, or family history of sudden cardiac arrest.
  7. Participants with a history of prolongation:

    1. QTcF ≥ 450 ms during screening;
    2. Hypocalcemia or family history of long QT syndrome;
    3. Use of QT/QTc-prolonging medications;
    4. abnormalities deemed by the Investigator.
  8. Tobacco or nicotine product use within 3 months prior to screening or during the study until discharge.
  9. Use of other investigational drugs within 40 days prior to enrollment or within ≥ 5 half-lives (whichever is longer).
  10. Positive infectious disease screening results during screening ( antibody, , antibody).
  11. Clinically significant laboratory abnormalities per Investigator judgment during screening.
  12. Presence of clinically significant hypertension, defined as systolic blood pressure (SBP) > 145 mmHg and/or diastolic blood pressure (DBP) > 90 mmHg, at Screening or Admission.
  13. Blood loss > 50 mL within 40 days or > 500 mL within 56 days prior to dosing.
  14. Regular alcohol consumption (> 1 unit/day) within 1 month prior to screening or positive alcohol test at screening or admission. [1 unit = 150 mL wine, 360 mL beer, or 45 mL 40% alcohol]. Alcohol consumption within 48 hours predose or during CRU stays.
  15. Prescription/OTC medication use within 14 days prior to admission (Day -1) or ≥ 5 half-lives (whichever is longer); or use of any of the inhibitors or induces as listed in Appendix 1, -, p-glycoprotein- (p-gp) or breast cancer resistance protein (BCRP)-modulating substances (e.g., herbs, grapefruit) within 14 days predose or ≥ 5 half-lives.
  16. Thyroid disease history or clinically significant thyroid test abnormalities.
  17. to thyroid medications.
  18. Conditions potentially affecting drug ADME (e.g., gastrectomy, cholecystectomy, inflammatory bowel disease).
  19. Clinically significant comorbidities (e.g., GI, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardiovascular diseases) that may compromise study conduct/interpretation or pose risks per Investigator assessment.
  20. Hypersensitivity to investigational drug components, specific allergy history (asthma, urticaria, eczema), or atopic predisposition (allergy to ≥ 2 drugs/foods like milk/pollen).
  21. Any condition deemed by the Investigator to jeopardize participant safety or study integrity.
  22. Abnormal thyroid function tests (total/free T3, total/free T4, TSH) beyond reference ranges during screening.
  23. Troponin > during screening or Day -1 periods.
  24. Presence of any psychiatric disorder or impaired mental capacity that may compromise the ability to provide , affect the assessment of efficacy, or impair compliance with the study protocol.
  25. Any other condition that, in the opinion of the investigator, may jeopardize the safety of the subject or compromise the quality of the clinical study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    MAD Cohort 1: CS060380 1.0 mg

    CS060380 1.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions.

    Drug: CS060380 · Drug: Placebo

  • Experimental
    MAD Cohort 2: CS060380 2.0 mg

    CS060380 2.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions.

    Drug: CS060380 · Drug: Placebo

  • Experimental
    MAD Cohort 3: CS060380 4.0 mg

    CS060380 4.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions.

    Drug: CS060380 · Drug: Placebo

Interventions

  • CS060380 is administered orally once daily (QD)

  • DrugPlacebo

    Matching placebo is administered orally once daily (QD)

    Also known as: CS060380 Placebo

06

What researchers measure

Primary outcomes

  1. Adverse Events during the study period

    To characterize the safety and tolerability of multiple doses of CS060380 in healthy participants

    Time frame: Baseline to Day28

Secondary outcomes

  1. Cmax

    Pharmacokinetics: Maximum concentration during a dosing interval

    Time frame: Day1

  2. Tmax

    Pharmacokinetics: Time to maximum plasma concentration

    Time frame: Day1 Day17

  3. t1/2

    Pharmacokinetics: Terminal elimination half-life

    Time frame: Day1

  4. AUClast

    Pharmacokinetics: AUC from time 0 to the last measurable concentration

    Time frame: Day1

  5. AUCinf

    Pharmacokinetics: area under the plasma concentration-time curve from time zero to infinity

    Time frame: Day1

  6. CL/F

    Pharmacokinetics: apparent total plasma clearance

    Time frame: Day1

  7. Cmax,ss

    Pharmacokinetics: steady-state maximum plasma concentration

    Time frame: Day14

  8. Cmin

    Pharmacokinetics: minimum concentration during a dosing interval

    Time frame: Day14

  9. t1/2,ss

    Pharmacokinetics: steady-state terminal elimination half-life

    Time frame: Day14

  10. AUCτ (τ = 24 hours)

    Pharmacokinetics: AUC from time 0 to 24 hours after dosing

    Time frame: Day14

  11. CL/Fss

    Pharmacokinetics: steady-State apparent total plasma clearance

    Time frame: Day14

  12. DF

    Pharmacokinetics: degree of fluctuation

    Time frame: Day14

  13. Cavg

    Pharmacokinetics: mean plasma concentration during a dosing interval

    Time frame: Day14

  14. Rac_AUCτ

    Pharmacokinetics: accumulation ratio based on area under the plasma concentration-time curve

    Time frame: Day14

Other outcomes

  1. LDL-C

    Pharmacodynamics: low-density lipoprotein cholesterol

    Time frame: Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17

  2. HDL-C

    Pharmacodynamics: high-density lipoprotein cholesterol

    Time frame: Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

  3. TG

    Pharmacodynamics: triglycerides

    Time frame: Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17

  4. TC

    Pharmacodynamics: total cholesterol

    Time frame: Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17

  5. SHBG

    Pharmacodynamics: sex hormone binding globulin

    Time frame: Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17

  6. Total/free T3

    To explore the effects on thyroid function parameters of CS060380

    Time frame: Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

  7. total/free T4,

    To explore the effects on thyroid function parameters of CS060380

    Time frame: Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

  8. TSH

    To explore the effects on thyroid function parameters of CS060380

    Time frame: Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

07

Study locations

1 site
  • Pharmaron Clinical Pharmacology Center (CPC), Inc.
    Baltimore, Maryland 21201, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.

Of 22 phase 1 interventional studies under Fatty Liver, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 18, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Mar 15, 2027
CompletionEst.
Apr 15, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07946341
Lead sponsor
Cascade Pharmaceuticals, Inc
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Mar 15, 2027 (estimated)
Completion
Apr 15, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Mary Purucker, MD
Contact
mary.purucker@pharmaron-us.com
+1-240-673-0500 ext. 1733
Mary Purucker, MD
principal investigator · Pharmaron Clinical Pharmacology Center (CPC), Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CS060380

Start the discussion